MX2018010401A - Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. - Google Patents
Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3.Info
- Publication number
- MX2018010401A MX2018010401A MX2018010401A MX2018010401A MX2018010401A MX 2018010401 A MX2018010401 A MX 2018010401A MX 2018010401 A MX2018010401 A MX 2018010401A MX 2018010401 A MX2018010401 A MX 2018010401A MX 2018010401 A MX2018010401 A MX 2018010401A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- combination
- angptl3
- pcsk9
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención provee métodos para tratar a pacientes que padecen hipercolesterolemia, en donde el paciente no responde, no es controlado adecuadamente o es intolerante al tratamiento con una terapia de modificación de lípidos estándar. Los métodos de la invención proveen la reducción de al menos un parámetro lipídico en el paciente administrando una cantidad terapéuticamente efectiva de un anticuerpo o fragmento de unión a antígeno del mismo que se une específicamente a la proproteína convertasa subtilisina/kexina tipo 9 (PCSK9) en combinación con una cantidad terapéuticamente efectiva de un anticuerpo que se une específicamente a la proteína similar a la angiopoyetina 3 (ANGPTL3). La combinación de un anticuerpo anti-PCSK9 con un anticuerpo anti-ANGPTL3 es útil en el tratamiento de enfermedades tales como la hipercolesterolemia, incluida la hipercolesterolemia familiar (FH), tanto heFH como hoHF, así como hiperlipidemia, hiperlipoproteinemia y dislipidemia, incluyendo hipertrigliceridemia, quilomicronemia, y para prevenir o tratar enfermedades o trastornos, para los cuales el metabolismo anormal de los lípidos es un factor de riesgo, tales como las enfermedades cardiovasculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302907P | 2016-03-03 | 2016-03-03 | |
| PCT/US2017/020221 WO2017151783A1 (en) | 2016-03-03 | 2017-03-01 | Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018010401A true MX2018010401A (es) | 2019-03-06 |
Family
ID=58361088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010401A MX2018010401A (es) | 2016-03-03 | 2017-03-01 | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20170253666A1 (es) |
| EP (1) | EP3423157A1 (es) |
| JP (3) | JP2019512472A (es) |
| KR (1) | KR102456731B1 (es) |
| CN (1) | CN109069868B (es) |
| AU (1) | AU2017227713B2 (es) |
| CA (1) | CA3016764A1 (es) |
| EA (1) | EA201891979A1 (es) |
| IL (1) | IL261420A (es) |
| MA (1) | MA43734A (es) |
| MX (1) | MX2018010401A (es) |
| WO (1) | WO2017151783A1 (es) |
| ZA (1) | ZA201805403B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
| US20220380425A1 (en) * | 2019-07-04 | 2022-12-01 | Cadila Healthcare Limited | Angptl3 based vaccine for the treatment of liver disease |
| US20240141029A1 (en) * | 2021-03-05 | 2024-05-02 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| US10111953B2 (en) * | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| CN107206068A (zh) * | 2014-07-16 | 2017-09-26 | 赛诺菲生物技术公司 | 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法 |
-
2017
- 2017-03-01 KR KR1020187028068A patent/KR102456731B1/ko active IP Right Grant
- 2017-03-01 US US15/446,720 patent/US20170253666A1/en not_active Abandoned
- 2017-03-01 JP JP2018545828A patent/JP2019512472A/ja active Pending
- 2017-03-01 CA CA3016764A patent/CA3016764A1/en active Pending
- 2017-03-01 CN CN201780014857.0A patent/CN109069868B/zh active Active
- 2017-03-01 MA MA043734A patent/MA43734A/fr unknown
- 2017-03-01 AU AU2017227713A patent/AU2017227713B2/en active Active
- 2017-03-01 EP EP17712283.5A patent/EP3423157A1/en active Pending
- 2017-03-01 WO PCT/US2017/020221 patent/WO2017151783A1/en active Application Filing
- 2017-03-01 MX MX2018010401A patent/MX2018010401A/es unknown
- 2017-03-01 EA EA201891979A patent/EA201891979A1/ru unknown
-
2018
- 2018-08-14 ZA ZA2018/05403A patent/ZA201805403B/en unknown
- 2018-08-28 IL IL261420A patent/IL261420A/en unknown
-
2020
- 2020-03-03 US US16/808,058 patent/US20200199253A1/en active Pending
-
2022
- 2022-03-16 JP JP2022040874A patent/JP2022078306A/ja active Pending
-
2024
- 2024-02-22 JP JP2024025078A patent/JP2024059787A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024059787A (ja) | 2024-05-01 |
| US20200199253A1 (en) | 2020-06-25 |
| JP2019512472A (ja) | 2019-05-16 |
| CA3016764A1 (en) | 2017-09-08 |
| EA201891979A1 (ru) | 2019-01-31 |
| KR102456731B1 (ko) | 2022-10-24 |
| CN109069868B (zh) | 2023-06-06 |
| IL261420A (en) | 2018-10-31 |
| MA43734A (fr) | 2018-11-28 |
| WO2017151783A1 (en) | 2017-09-08 |
| JP2022078306A (ja) | 2022-05-24 |
| AU2017227713B2 (en) | 2022-12-22 |
| ZA201805403B (en) | 2019-08-28 |
| AU2017227713A1 (en) | 2018-09-13 |
| KR20180118181A (ko) | 2018-10-30 |
| CN109069868A (zh) | 2018-12-21 |
| EP3423157A1 (en) | 2019-01-09 |
| US20170253666A1 (en) | 2017-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018012221A (es) | Metodos para tratar hiperlipidemia con un inhibidor de proteina tipo angiopoyetina 8 y un inhibidor de proteina tipo angiopoyetina 3. | |
| MX2018012741A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia familiar. | |
| MX2018010401A (es) | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. | |
| EA201691847A1 (ru) | Способы снижения сердечно-сосудистого риска | |
| MX2020009246A (es) | Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular. | |
| MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| EA201391668A1 (ru) | Способы лечения или предупреждения связанных с холестерином расстройств | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| EA201792336A2 (ru) | Способы лечения или предупреждения связанных с холестерином расстройств | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| MX363350B (es) | COMPUESTOS DE SULFONA BICÍCLICA PARA LA INHIBICIÓN DE LA ACTIVIDAD RORgamma Y EL TRATAMIENTO DE ENFERMEDADES. | |
| EP3749264C0 (en) | LASER THERAPY FOR TREATMENT AND PREVENTION OF EYE DISEASES | |
| NZ704771A (en) | Anti-pcsk9 antibodies with ph-dependent binding characteristics | |
| MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
| JO3412B1 (ar) | أجسام مضادة ل angptl3 واستخداماتها | |
| MX2021000289A (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| IL284699A (en) | Treatment of diseases associated with enpp1 or enpp3 deficiency | |
| MX2021009413A (es) | Materiales y métodos para tratar una enfermedad neurodegenerativa. | |
| EA201892444A1 (ru) | Способы лечения пациентов с семейной гиперхолестеринемией | |
| EA201990559A1 (ru) | Комбинированная терапия | |
| EA201892272A1 (ru) | Способы лечения гиперлипидемии ингибитором angptl8 и ингибитором angptl3 |